BI in cancer antibody discovery deal with Oxford BioTherapeutics
UK oncology drug and companion diagnostic developer Oxford BioTherapeutics Ltd. (OBT) has licensed Boehringer Ingelheim GMBH exclusive rights to develop and market its cancer antibodies.
Drug Discovery Tools
- Molecular Diversity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com